KQED Radio Staff
Amy Standen is a radio reporter for QUEST, KQED's science and environment show. She was born and raised in San Francisco, but cut her teeth in public radio at New York City's KPFA. Since then, she's been a producer on Pulse of the Planet, editor of Terrain Magazine and an editor at Salon, and a "roving reporter" for KALW's Philosophy Talk. These days, she reports features and news spots for KQED News and QUEST and contributes frequently to NPR.
A recipient of the James Madison Freedom of Information Award, Amy's work has also been recognized by the National Association of Public Radio News Directors and Northern California's Society of Professional Journalists.
Email Amy: email@example.com
Call Amy: (415) 553-2105
Stories (245 archives)
In the updated "Bible of psychiatry," the Diagnostic and Statistical Manual of Mental Disorders, there's a new category called the Obsessive Compulsive Spectrum. It includes not just OCD, but other behaviors that are far more common.
The field of psychiatry is going through major changes this year. For the first time in almost two decades, the so-called "Bible" of psychiatry -- the "Diagnostic and Statistical Manual of Mental Disorders" -- is getting an overhaul. Among the changes: a new category called the Obsessive Compulsive Spectrum. That includes not just OCD, but other behaviors that are far more common.
If Proposition 37 passes, California would be the first state to require manufacturers to label foods made with genetically modified ingredients. Critics of the measure say that such a label would be a veritable scarlet letter for products, while supporters site a lack of research on the effects of Genetically Modified Organisms.
The funding gap is widening in one of the most closely watched items on California's November ballot. Proposition 37 would require labels on all foods containing genetically modified ingredients.
More than 34 million people live with HIV/AIDS worldwide. Only one person has, apparently, been cured of the virus. As the International AIDS Conference returns to the U.S. for the first time in more than 20 years, we speak with two individuals: the man known in some research circles as "the Berlin Patient," and one of the California researchers trying to replicate his HIV cure using gene therapy.